Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RGS12 | O14924 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21703085 | 0.89 | MAP4K1 (0.38) | MAP4K1KDM4EALDH1A1 | |
| SCHEMBL21702894 | 0.85 | MAP4K1 (0.36) | MAP4K1ELANE | |
| SCHEMBL21702897 | 0.82 | MEN1 (0.38) | MAP4K1KDM4EMEN1RGS12USP2 | |
| SCHEMBL21685592 | 0.77 | MAP4K1 (0.46) | MAP4K1ELANE | |
| SCHEMBL23453061 | 0.77 | MAP4K1 (0.39) | MAP4K1ELANEMEN1POLBMAPT | |
| SCHEMBL21703150 | 0.75 | MAP4K1 (0.46) | MAP4K1KDM4EALDH1A1 | |
| SCHEMBL25949329 | 0.75 | MAP4K1 (0.52) | MAP4K1 | |
| SCHEMBL21685522 | 0.74 | MAP4K1 (0.45) | MAP4K1 | |
| SCHEMBL21702899 | 0.74 | MAP4K1 (0.46) | MAP4K1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL25938264 | 0.74 | MAP4K1 (0.36) | MAP4K1ELANEKDM4EMEN1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |